Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medacta : Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spine Pathologies

10/13/2020 | 01:00pm EST

EQS Group-News: Medacta Group SA / Key word(s): Market launch
Medacta Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spine Pathologies

13.10.2020 / 19:00


Media Release

Medacta Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spine Pathologies

CASTEL SAN PIETRO, 13 October 2020 - Medacta is proud to announce the release of the M.U.S.T. 2.0 instrumentation, a next generation solution for spine surgery designed to simplify the procedure and provide robust instruments in open surgery when treating degenerative spine pathologies.

The M.U.S.T. 2.0 system is the next generation of M.U.S.T. instruments that incorporates an upgraded geometrical design to support every single step of the surgery. A new innovation in material technology with the addition of a thin carbon film coating ensures superior instrument performance and durability thanks to wear-resistant properties.

The M.U.S.T. 2.0 has been designed in collaboration with the Balgrist University Hospital in Zurich, Switzerland, thus being developed with an optimal insight in clinical experience together with an engineering foundation.

After providing solid support to the design phase of the M.U.S.T. 2.0 system, Prof. Dr. med. Mazda Farshad, Medical Director, Chief of Orthopaedics and Chief of Division of Spine Surgery at the Balgrist University Hospital, has successfully accomplished the first series of spine surgeries with optimal initial outcomes. "The evolution of the M.U.S.T. spinal instrumentation was strongly driven by cognizant observations of each surgical step and incremental improvements. The M.U.S.T. 2.0 is a reliable system based on established concepts and innovations that simplify the surgical flow of spinal procedure," said Prof. Farshad.

The M.U.S.T. 2.0 instrumentation is used to implant the Medacta M.U.S.T. (Medacta Universal Screw Technology) pedicle screw system, a universal polyaxial screw, rod and connector system applicable to degenerative, deformity and trauma cases.

Medacta is continuing to deliver optimal solutions to surgeons for the benefit of their patients, and M.U.S.T. 2.0 represents a further expansion of the fast-growing Medacta spine portfolio.

For more information on the Medacta spine surgery solutions, please visit spine.medacta.com


Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated MySolutions technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch,investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1140544

 
End of News EQS Group News Service

1140544  13.10.2020 

fncls.ssp?fn=show_t_gif&application_id=1140544&application_name=news&site_id=zonebourse_sftp

© EQS 2020
All news about MEDACTA GROUP SA
02/18MEDACTA : First U.S. Anterior Cruciate Ligament Reconstruction with M-ARS ACL
PU
02/15MEDACTA : Gets US FDA Nod for MyHip Planner, Verifier Tools
MT
02/15MEDACTA : Adds the MyHip Planner and the MyHip Verifier Tools to its Personalize..
PU
02/15EQS-NEWS : Medacta Adds the MyHip Planner and the MyHip Verifier Tools to its Pe..
DJ
01/25MEDACTA : Octavian Lifts Price Target on Medacta Group, Maintains Buy Recommenda..
MT
01/21MEDACTA : FY20 Revenue Slips 3% Amid Growth Slump Across Product Line
MT
01/21MEDACTA : 2020 Preliminary unaudited top-line figures Read More >
PU
01/21EQS-ADHOC : 2020 Preliminary unaudited top-line -2-
DJ
01/21MEDACTA : 2020 Preliminary unaudited top-line figures
EQ
01/04MEDACTA : announces the results of today's Extraordinary General Meeting Read Mo..
PU
More news
Financials
Sales 2020 300 M 365 M 365 M
Net income 2020 29,7 M 36,1 M 36,1 M
Net Debt 2020 113 M 138 M 138 M
P/E ratio 2020 63,1x
Yield 2020 0,42%
Capitalization 1 902 M 2 312 M 2 312 M
EV / Sales 2020 6,71x
EV / Sales 2021 5,63x
Nbr of Employees 1 126
Free-Float 30,5%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 80,41 €
Last Close Price 95,11 €
Spread / Highest target 5,47%
Spread / Average Target -15,4%
Spread / Lowest Target -38,5%
EPS Revisions
Managers and Directors
NameTitle
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Riccardo Braglia Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA19.63%2 325
ABBOTT LABORATORIES11.93%214 001
MEDTRONIC PLC-1.19%159 002
BECTON, DICKINSON AND COMPANY-1.01%71 972
HOYA CORPORATION-13.00%45 798
ALIGN TECHNOLOGY, INC.8.45%44 772